{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Rare+Tumors&page=2", "query": { "condition": "Rare Tumors", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Rare+Tumors&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-07-23T17:46:38.478Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06010329", "title": "A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Sutetinib Maleate Capsule", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Teligene US", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 66, "start_date": "2023-12-27", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-04-24", "last_synced_at": "2026-07-23T17:46:38.478Z", "location_count": 9, "location_summary": "Glendale, California • La Jolla, California • Tampa, Florida + 6 more", "locations": [ { "city": "Glendale", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Athens", "state": "Georgia" }, { "city": "Des Moines", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT06010329" }, { "nct_id": "NCT01755195", "title": "Cabozantinib for Adults With Advanced Soft Tissue Sarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Refractory Soft Tissue Sarcomas" ], "interventions": [ { "name": "Cabozantinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 55, "start_date": "2013-01-15", "completion_date": "2023-09-11", "has_results": true, "last_update_posted_date": "2024-01-03", "last_synced_at": "2026-07-23T17:46:38.478Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01755195" }, { "nct_id": "NCT05715281", "title": "Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Rare Malignant Solid Neoplasm", "Rare Malignant Solid Neoplasm", "Refractory Rare Malignant Solid Neoplasm" ], "interventions": [ { "name": "Atezolizumab", "type": "BIOLOGICAL" }, { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Tiragolumab", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2023-09-26", "completion_date": "2026-11-21", "has_results": false, "last_update_posted_date": "2025-11-25", "last_synced_at": "2026-07-23T17:46:38.478Z", "location_count": 3, "location_summary": "Bethesda, Maryland • Columbus, Ohio", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05715281" }, { "nct_id": "NCT03434418", "title": "A Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR Mutations", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "osimertinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2018-06-30", "completion_date": "2022-10-12", "has_results": true, "last_update_posted_date": "2023-10-17", "last_synced_at": "2026-07-23T17:46:38.478Z", "location_count": 3, "location_summary": "Durham, North Carolina • Columbus, Ohio • Pittsburgh, Pennsylvania", "locations": [ { "city": "Durham", "state": "North Carolina" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03434418" }, { "nct_id": "NCT07185997", "title": "Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-Small-Cell Lung Cancer", "Metastatic Non-Small-Cell Lung Cancer", "Advanced Non-Small-Cell Lung Cancer", "EGFR P-Loop and Alpha C-Helix Compressing", "EGFR PACC", "EGFR Uncommon Mutations" ], "interventions": [ { "name": "Firmonertinib", "type": "DRUG" }, { "name": "EGFR-TKI inhibitor based on investigator's choice", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ArriVent BioPharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 480, "start_date": "2025-12-17", "completion_date": "2030-12", "has_results": false, "last_update_posted_date": "2026-07-02", "last_synced_at": "2026-07-23T17:46:38.478Z", "location_count": 17, "location_summary": "Los Angeles, California • Sacramento, California • San Francisco, California + 14 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Vallejo", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT07185997" }, { "nct_id": "NCT07128199", "title": "A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "NSCLC, Stage IB-IIIA", "Lung Cancer", "Adjuvant", "Post-surgical", "EGFR", "Exon 20", "Early Stage Lung Cancer", "Uncommon EGFR Mutations" ], "interventions": [ { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "TAS6417", "type": "DRUG" }, { "name": "Zipalertinib Matching-placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Taiho Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 360, "start_date": "2025-12-22", "completion_date": "2032-10-01", "has_results": false, "last_update_posted_date": "2026-06-26", "last_synced_at": "2026-07-23T17:46:38.478Z", "location_count": 30, "location_summary": "Anchorage, Alaska • Duarte, California • Irvine, California + 26 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Vallejo", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07128199" }, { "nct_id": "NCT04084067", "title": "Indocyanine Green (ICG) Guided Tumor Resection", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplastic Disease", "Solid Tumor" ], "interventions": [ { "name": "Indocyanine Green", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 230, "start_date": "2020-02-07", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-04-30", "last_synced_at": "2026-07-23T17:46:38.478Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04084067" }, { "nct_id": "NCT00898079", "title": "Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Acute Undifferentiated Leukemia", "Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative", "Childhood Acute Lymphoblastic Leukemia", "Childhood Acute Myeloid Leukemia", "Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Childhood Solid Neoplasm", "Chronic Lymphocytic Leukemia", "Hairy Cell Leukemia", "Juvenile Myelomonocytic Leukemia", "Mast Cell Leukemia", "Neoplasm of Uncertain Malignant Potential", "Prolymphocytic Leukemia", "Secondary Acute Myeloid Leukemia", "T-Cell Large Granular Lymphocyte Leukemia" ], "interventions": [ { "name": "Cytology Specimen Collection Procedure", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "30 Years", "sex": "ALL", "summary": "Up to 30 Years" }, "enrollment_count": 2545, "start_date": "2003-10-13", "completion_date": "2018-06-30", "has_results": false, "last_update_posted_date": "2018-07-19", "last_synced_at": "2026-07-23T17:46:38.478Z", "location_count": 175, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 132 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00898079" }, { "nct_id": "NCT05350761", "title": "Rare Tumors and Cancer Predisposition in Individuals and Families", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cancer", "Hereditary Neoplasms", "Genetic Predisposition to Cancer", "Environment" ], "interventions": [], "intervention_types": [], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 500, "start_date": "2023-03-10", "completion_date": "2035-12-31", "has_results": false, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-07-23T17:46:38.478Z", "location_count": 2, "location_summary": "Bethesda, Maryland • Rockville, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Rockville", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05350761" }, { "nct_id": "NCT03340506", "title": "Dabrafenib and/or Trametinib Rollover Study", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Melanoma", "Non Small Cell Lung Cancer", "Solid Tumor", "Rare Cancers", "High Grade Glioma" ], "interventions": [ { "name": "dabrafenib", "type": "DRUG" }, { "name": "trametinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 100, "start_date": "2018-01-26", "completion_date": "2032-12-28", "has_results": false, "last_update_posted_date": "2026-07-09", "last_synced_at": "2026-07-23T17:46:38.478Z", "location_count": 4, "location_summary": "Scottsdale, Arizona • Bethesda, Maryland • Columbus, Ohio + 1 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03340506" } ] }